Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Inhibition of DOT1L and PRMT5 Promotes Anti-Tumor Activity in a Human MLL Leukemia Model Induced By CRISPR/Cas9

Kathy-Ann Secker, MSc, Hildegard Keppeler, Silke Duerr-Stoerzer, Hannes Schmid, MSc, Dominik Schneidawind, MD, Thomas Hentrich, PhD, Julia Schulze-Hentrich, PhD, Barbara Mankel, Falko Fend, MD, Lothar Kanz, Corina Schneidawind, MD

Blood (2018) 132 (Supplement 1): 5147.

https://doi.org/10.1182/blood-2018-99-115975

Published: 2018

Journal Articles

Invariant Natural Killer T Cells from Donor Lymphocyte Infusions (DLI-iNKTs) Contribute to Anti-Tumor Immunity after Allogeneic Hematopoietic Cell Transplantation

Simona Jahnke, Hannes Schmid, MSc, Kathy-Ann Secker, MSc, Silke Duerr-Stoerzer, Hildegard Keppeler, Rebecca Baur, Michael Schumm, Dr. MD vet., Rupert Handgretinger, MD PhD, Wolfgang Bethge, MD, Lothar Kanz, Corina Schneidawind, MD, Dominik Schneidawind, MD

Blood (2018) 132 (Supplement 1): 3340.

https://doi.org/10.1182/blood-2018-99-111745

Published: 2018

Journal Articles

Myc Drives MLL Leukemogenesis in a Human CRISPR/Cas9 Leukemia Model and Indirect Inhibition with JQ1 Diminishes Leukemia Activity

Kathy-Ann Secker, MSc, Hildegard Keppeler, Silke Duerr-Stoerzer, Hannes Schmid, MSc, Dominik Schneidawind, MD, Thomas Hentrich, PhD, Julia Schulze-Hentrich, PhD, Lothar Kanz, Corina Schneidawind, MD

Blood (2018) 132 (Supplement 1): 2213.

https://doi.org/10.1182/blood-2018-99-114419

Published: 2018

Journal Articles

Increased Activity in the T Cell Effector Phase and Enhanced T Cell Repertoire Target-Tissue Stability Distinguish Alloreactivity Across Major Versus Minor Histocompatibility Barriers

Pingping Zheng, PhD, Adrianne E Vasey, Jeanette Baker, Bettina Iliopoulou, PhD, Dennis B Leveson-Gower, PhD, Antonio Pierini, Dominik Schneidawind, MD, Xiaoqing You, PhD, Katie Hsu, Robert Negrin, MD, Everett Meyer, MD PhD

Blood (2015) 126 (23): 4284.

https://doi.org/10.1182/blood.V126.23.4284.4284

Published: 2015

Journal Articles

Expanded CD4+Foxp3+ Regulatory T Cells through DR3 Signaling Have a Distinct Immunophenotype and Abrogate the Lethal Acute-Graft and Host Disease after Allogeneic Transplantation

Hidekazu Nishikii, MD, PhD, Byung-Su Kim, MD, Yasuhisa Yokoyama, MD,PhD, Jeanette Baker, PhD, Antonio Pierini, MD, Maite Alvarez, PhD, Yuqiong Pan, MD, PhD, Yan Chen, MD, Dominik Schneidawind, MD, Shigeru Chiba, MD, PhD, Robert Negrin, MD

Blood (2015) 126 (23): 1876.

https://doi.org/10.1182/blood.V126.23.1876.1876

Published: 2015

Journal Articles

TNF-Alpha Priming Enhances CD4 + FoxP3 + Regulatory T Cell Suppressive Function in GvHD Prevention and Treatment

Antonio Pierini, MD, Caitlin Moffett, Dominik Schneidawind, MD, Jeanette Baker, PhD, Hidekazu Nishikii, MD PhD, Yuqiong Pan, MD, PhD, Maite Alvarez, PhD, Everett Meyer, MD PhD, Robert Negrin, MD

Blood (2015) 126 (23): 1885.

https://doi.org/10.1182/blood.V126.23.1885.1885

Published: 2015

Journal Articles

Loss of CD62L Expression in CD4+FoxP3+ Regulatory T Cells Following Freeze-and-Thaw Prevents Protection Against GVHD in Murine Models

Mareike Florek, MD, Dominik Schneidawind, MD, Jeanette Baker, PhD, Antonio Pierini, MD, Dennis B Leveson-Gower, PhD, Yuqiong Pan, MD, Robert S. Negrin, MD, Everett H. Meyer, MD PhD

Blood (2014) 124 (21): 2427.

https://doi.org/10.1182/blood.V124.21.2427.2427

Published: 2014

Journal Articles

Genome Engineering to Prospectively Investigate the Pathogenesis of MLL-AF9 Acute Leukemia

Corina Buechele, MD, Erin H. Breese, MDPhD, Dominik Schneidawind, MD, Matthew H. Porteus, MD PhD, Michael L. Cleary, MD

Blood (2014) 124 (21): 883.

https://doi.org/10.1182/blood.V124.21.883.883

Published: 2014

Journal Articles

Activation of DR3 Signaling Expands Recipient Derived Regulatory T Cells and Enhances Donor Immune Reconstitution Derived from Allogeneic Hematopoietic Stem Cells

Hidekazu Nishikii, MD PhD, Byung Su Kim, MD, Antonio Pierini, MD, Jeanette Baker, PhD, Dominik Schneidawind, MD, Yuqiong Pan, MD, Maite Alvarez, PhD, Robert S. Negrin, MD

Blood (2014) 124 (21): 1087.

https://doi.org/10.1182/blood.V124.21.1087.1087

Published: 2014

Journal Articles

Third Party Invariant Natural Killer T Cells Protect from Graft-Versus-Host Disease Lethality through Expansion of Donor CD4 + FoxP3 + Regulatory T Cells

Dominik Schneidawind, MD, Jeanette Baker, PhD, Corina Buechele, MD, Everett H. Meyer, MD PhD, Robert S. Negrin, MD

Blood (2014) 124 (21): 3825.

https://doi.org/10.1182/blood.V124.21.3825.3825

Published: 2014

Journal Articles

Donor Requirements For CD4+CD25+FoxP3+ Regulatory T Cells Capable Of Suppressing CD4+ and CD8+ Conventional T Cell Proliferation and Graft Versus Host Disease

Antonio Pierini, MD, Lucrezia Colonna, PhD, Maite Alvarez, PhD, Dominik Schneidawind, MD, Byung-Su Kim, MD, Jeanette Baker, PhD, Robert Negrin, MD

Blood (2013) 122 (21): 4484.

https://doi.org/10.1182/blood.V122.21.4484.4484

Published: 2013

Journal Articles

Adoptive Transfer Of Ex Vivo “Educated” CD4+CD25+FoxP3+ Regulatory T Cells Effectively Treats Acute Graft Versus Host Disease Preserving Graft Versus Tumor Effect

Antonio Pierini, MD, Dominik Schneidawind, MD, Mareike Florek, MD, Maite Alvarez, PhD, Yuqiong Pan, MD, Jeanette Baker, PhD, Everett Meyer, MD, PhD, Robert Negrin, MD

Blood (2013) 122 (21): 4485.

https://doi.org/10.1182/blood.V122.21.4485.4485

Published: 2013

Journal Articles

CD4+ Invariant Natural Killer T Cells Require NKG2D To Protect From Lethal Acute Graft-Versus-Host Disease

Dominik Schneidawind, MD, Antonio Pierini, MD, Maite Alvarez, PhD, Yuqiong Pan, MD, Jeanette Baker, PhD, Everett Meyer, MD, PhD, Robert Negrin, MD

Blood (2013) 122 (21): 898.

https://doi.org/10.1182/blood.V122.21.898.898

Published: 2013

Journal Articles

Agonistic Anti-DR3 Antibody Expands Treg and Reduces Experimental Acute Graft-Versus-Host Disease

Byung-Su Kim, MD, Antonio Pierini, MD, Dominik Schneidawind, MD, Jeanette Baker, PhD, Hidekazu Nishikii, MD, PhD, Yuqiong Pan, MD, Maite Alvarez, PhD, Robert Negrin, MD

Blood (2013) 122 (21): 135.

https://doi.org/10.1182/blood.V122.21.135.135

Published: 2013

Journal Articles

Delayed Immune Reconstitution After Allogeneic Hematopoietic Cell Transplantation with Yttrium-90 Ibritumomab Tiuxetan-Based Reduced-Intensity Conditioning

Dominik Schneidawind, MD, Sebastian Jendryssek, Birgit Federmann, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A Bethge, MD

Blood (2012) 120 (21): 4482.

https://doi.org/10.1182/blood.V120.21.4482.4482

Published: 2012

Journal Articles

Reduced-Intensity Conditioning with Fludarabine and Busulfan: Age Has No Negative Impact On Survival

Dominik Schneidawind, MD, Birgit Federmann, MD, Andrea Helwig, Wichard Vogel, MD, Christoph Faul, MD, Lothar Kanz, MD, Wolfgang A Bethge, MD

Blood (2012) 120 (21): 2041.

https://doi.org/10.1182/blood.V120.21.2041.2041

Published: 2012

Journal Articles

Salvage Allogeneic Hematopoietic Cell Transplantation for Relapsed or Progressive Multiple Myeloma After Autologous Hematopoietic Cell Transplantation

Dominik Schneidawind, MD, Katharina Oehrlein, MD, Katja C Weisel, MD, Christoph Faul, MD, Lothar Kanz, MD, Wolfgang A Bethge, MD

Blood (2012) 120 (21): 2043.

https://doi.org/10.1182/blood.V120.21.2043.2043

Published: 2012

Journal Articles

Allogeneic Hematopoietic Cell Transplantation with FLAMSA-RIC Can Overcome the Poor Prognosis of Primary Refractory or Relapsed AML

Dominik Schneidawind, MD, Birgit Federmann, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A. Bethge, MD

Blood (2011) 118 (21): 1938.

https://doi.org/10.1182/blood.V118.21.1938.1938

Published: 2011

NARROW

Inhibition of DOT1L and PRMT5 Promotes Anti-Tumor Activity in a Human MLL Leukemia Model Induced By CRISPR/Cas9

Invariant Natural Killer T Cells from Donor Lymphocyte Infusions (DLI-iNKTs) Contribute to Anti-Tumor Immunity after Allogeneic Hematopoietic Cell Transplantation

Myc Drives MLL Leukemogenesis in a Human CRISPR/Cas9 Leukemia Model and Indirect Inhibition with JQ1 Diminishes Leukemia Activity

Increased Activity in the T Cell Effector Phase and Enhanced T Cell Repertoire Target-Tissue Stability Distinguish Alloreactivity Across Major Versus Minor Histocompatibility Barriers

Expanded CD4+Foxp3+ Regulatory T Cells through DR3 Signaling Have a Distinct Immunophenotype and Abrogate the Lethal Acute-Graft and Host Disease after Allogeneic Transplantation

TNF-Alpha Priming Enhances CD4 + FoxP3 + Regulatory T Cell Suppressive Function in GvHD Prevention and Treatment

Loss of CD62L Expression in CD4+FoxP3+ Regulatory T Cells Following Freeze-and-Thaw Prevents Protection Against GVHD in Murine Models

Genome Engineering to Prospectively Investigate the Pathogenesis of MLL-AF9 Acute Leukemia

Activation of DR3 Signaling Expands Recipient Derived Regulatory T Cells and Enhances Donor Immune Reconstitution Derived from Allogeneic Hematopoietic Stem Cells

Third Party Invariant Natural Killer T Cells Protect from Graft-Versus-Host Disease Lethality through Expansion of Donor CD4 + FoxP3 + Regulatory T Cells

Donor Requirements For CD4+CD25+FoxP3+ Regulatory T Cells Capable Of Suppressing CD4+ and CD8+ Conventional T Cell Proliferation and Graft Versus Host Disease

Adoptive Transfer Of Ex Vivo “Educated” CD4+CD25+FoxP3+ Regulatory T Cells Effectively Treats Acute Graft Versus Host Disease Preserving Graft Versus Tumor Effect

CD4+ Invariant Natural Killer T Cells Require NKG2D To Protect From Lethal Acute Graft-Versus-Host Disease

Agonistic Anti-DR3 Antibody Expands Treg and Reduces Experimental Acute Graft-Versus-Host Disease

Delayed Immune Reconstitution After Allogeneic Hematopoietic Cell Transplantation with Yttrium-90 Ibritumomab Tiuxetan-Based Reduced-Intensity Conditioning

Reduced-Intensity Conditioning with Fludarabine and Busulfan: Age Has No Negative Impact On Survival

Salvage Allogeneic Hematopoietic Cell Transplantation for Relapsed or Progressive Multiple Myeloma After Autologous Hematopoietic Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation with FLAMSA-RIC Can Overcome the Poor Prognosis of Primary Refractory or Relapsed AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only